Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Velocity Pharmaceutical Development
South San Francisco, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Velocity Pharmaceutical Development employs an asset-centric virtual development model, creating single-product project-focused companies to advance licensed drugs through proof-of-concept with shared management and expertise. Tigercat Pharma's serlopitant (VPD-737) showed positive Phase 2 results for chronic pruritus in 2014.
- Therapeutic areas
- EndocrinologyPulmonologyDermatologyGastroenterology
- Modalities
- Small moleculePeptide
- Industry
- Biotech
02
Partnerships
MerckEuMederisPresidio PartnersRemeditex VenturesBaxaltaMayo Clinic
Beyond the preview
Go deeper on Velocity Pharmaceutical Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Velocity Pharmaceutical Development.